Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 27, 2005

View Archived Issues

Fc fragment is not necessary for 1G8's antitumor activity

Antidepressant efficacy of the selective mGluR5 antagonist, MTEP, shown in rodents

Peregrine evaluating Tarvacin Anti-Viral for influenza

In vivo efficacy of SL-65.0155 in Alzheimer's model

Rigel and Serono sign Aurora kinase inhibitor agreement

Cardiome Pharma completes acquisition of Artesian Therapeutics

Solbec selects tumor targets for trials of Coramsine

Surfaxin complete response accepted, new sublicense agreement signed

Epitan tests topical formulation of EPT-1647

FASgen awarded SBIR grant for work in obesity and metabolic disorders

Phase II trial discontinued for KOS-862 in hormone refractory prostate cancer

Aroplatin begins phase I study in solid tumors and B-cell lymphoma

Xencor raises funds to begin phase I trial of XPro1595

Enrollment stopped in phase III studies of ONO-4128

Revlimid MAA accepted for review

FDA to review iPlex complete response

MHRA accepts for review Dyoject MAA

SGX receives fast track status for Troxatyl for AML

Priority review granted for Rituxan sBLA

New data on the analgesic effects of gabapentin

Belatacept reported effective in renal transplant recipients at higher risk of CAN

Adjunctive levetiracetam reduces primary tonic-clonic seizures in patients with IGE

RJR-2403 assessed in Alzheimer's disease model

LY-156735 improves sleep parameters in moderate to severe insomnia

Reversal of neuromuscular block achieved with ORG-25969

Pegaptanib improves visual acuity in patients with diabetic macular edema

Recent patents disclose novel agents for the treatment of neurological disorders

Novel antiinfective agents disclosed in recent patent literature

Recent Cambridge Biotechnology patent reports novel analgesic agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...